TELA Bio, Inc. (TELA)
NASDAQ: TELA · IEX Real-Time Price · USD
4.570
-0.180 (-3.79%)
Apr 22, 2024, 4:00 PM EDT - Market closed

Company Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio, Inc.
TELA Bio logo
Country United States
Founded 2012
IPO Date Nov 8, 2019
Industry Medical Devices
Sector Healthcare
Employees 227
CEO Antony Koblish

Contact Details

Address:
1 Great Valley Parkway, Suite 24
Malvern, Pennsylvania 19355
United States
Phone 484-320-2930
Website telabio.com

Stock Details

Ticker Symbol TELA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001561921
CUSIP Number 872381108
ISIN Number US8723811084
Employer ID 45-5320061
SIC Code 3841

Key Executives

Name Position
Antony Koblish Co-founder, President, Chief Executive Officer and Director
Roberto E. Cuca J.D. Chief Financial Officer and Chief Operating Officer
Paul Talmo Chief Technology Officer
Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer and Principal Accounting Officer
D. Taylor Ocasio General Counsel and Corporate Secretary
Jennifer Lou Armstrong Senior Vice President of Human Resources
Gregory A. Firestone Chief Business Officer
Michael Leonard Senior Vice President of Technical Operations
Peter C. Murphy Chief Commercial Officer
Louisa Smith Investor Relations Contact Officer

Latest SEC Filings

Date Type Title
Apr 18, 2024 ARS Filing
Apr 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 18, 2024 DEF 14A Other definitive proxy statements
Apr 15, 2024 8-K Current Report
Mar 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 22, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Mar 20, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals